Ibandronsäure Stada

Ibandronic acid, the active ingredient in Ibandronsäure Stada, is a bisphosphonate presented as an intravenous solution for intravenous use. It treats osteoporosis and Paget's disease of bone in adults.

GNH USA supplies Ibandronsäure Stada as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ibandronic acid is a bisphosphonate that inhibits bone resorption and is indicated for the following conditions:

- Osteoporosis: reduces the risk of vertebral and hip fractures by decreasing bone turnover. - Paget's disease of bone: normalizes abnormal bone remodeling and alleviates bone pain.

Ibandronic acid may cause a range of adverse reactions. The most frequently reported events are generally mild and transient.

Common Side Effects: - Acute‑phase reaction: fever, chills, myalgia, and headache. - Nausea or vomiting. - Transient flu‑like symptoms. - Infusion site discomfort or pain. - Transient low calcium levels. - Mild rash.

Serious or Rare Side Effects: - Osteonecrosis of the jaw. - Atypical femur fracture. - Severe renal impairment or acute kidney injury. - Anaphylactic or severe hypersensitivity reactions.

Before initiating therapy with Ibandronic acid, several safety considerations should be observed.

- Renal function: assess baseline creatinine clearance and avoid use in severe renal impairment. - Calcium status: correct hypocalcemia and ensure adequate vitamin D levels prior to infusion. - Concomitant nephrotoxic drugs: avoid or monitor closely to reduce renal risk. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk; safety data are limited. - Infusion rate: administer according to prescribing information to minimise acute‑phase reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ibandronic acid can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent bisphosphonate therapy: may cause excessive suppression of bone turnover. - Severe renal impairment (eGFR <30 mL/min): heightened risk of nephrotoxicity. - Existing hypocalcemia: can worsen low calcium levels. - Live vaccines: may increase susceptibility to infection.

Moderate Interactions (Monitor Closely): - NSAIDs: may compound renal stress. - Aminoglycoside antibiotics: potential additive nephrotoxicity. - Loop diuretics: may affect calcium balance and increase risk of hypocalcemia.